Managing Antipsychotic-Induced Tardive Dyskinesia
Tóm tắt
Antipsychotic-induced tardive dyskinesia is a common and clinically significant hazard of long term antipsychotic therapy. The arrival of atypical antipsy-chotics has markedly improved the outlook: atypical antipsychotics are emerging as effective treatments and may also reduce the prevalence and incidence of tardive dyskinesia. In mild cases, careful monitoring of tardive dyskinesia by serial Abnormal Involuntary Movements Scale (AIMS) assessments may be the appropriate course. More severe tardive dyskinesia calls for intervention in order to treat the dyskinesia. Atypical antipsychotics and tocopherol (vitamin E) are effective and generally well tolerated treatment options for tardive dyskinesia. Tardive dyskinesia variants such as tardive dystonia and tardive akathisia tend to be more severe and difficult to treat compared with typical tardive dyskinesia. Prevention of tardive dyskinesia is possible through careful selection of patients for antipsychotic therapy, use of the lowest effective antipsychotic dosages, use of atypical rather than traditional antipsychotics and concurrent tocopherol administration. The clinician can now undertake the management of tardive dyskinesia with growing confidence.
Tài liệu tham khảo
Casey D, Toenniessen LM. Neuroleptic treatment in tardive dyskinesia: can it be developed into a clinical strategy for long-term treatment. In: Bannet J, Belmaker RH, editors. New directions in tardive dyskinesia research. Basel: Karger, 1983: 65–79
Woerner MG, Kane JM, Lieberman JA, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991; 11: 34–42
Kane JM, Woerner M, Borenstern M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986; 22: 254–8
Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52: 756–65
Gardos G, Cole JO. The evaluation and treatment of neurolep-tic-induced movement disorders. Harv Rev Psychiatry 1995; 3: 130–9
Guy W. ECDEU assessment manual for psychopharmacology. Rev. ed. Washington (DC): Department of Health, Education and Welfare, 1976
Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 1982; 9: 486–7
Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994; 151: 836–41
Cole JO, Samson JA, Wykoff W, et al. Tardive dyskinesia: predictors of course over five years [poster]. Annual Meeting of the American Psychiatric Association. 1998 May. Toronto (ON)
Chouinard G, Annable L, Ross-Chouinard A. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988; 8 (4 Suppl.): 21S–6S
Jeste DV, Lohr JB, Clark K, et al. Pharmacological treatments of tardive dyskinesia in the 1980s. J Clin Psychopharmacol 1988; 8 (4 Suppl.): 38S–48S
Kane JM, Jeste DV, Barnes TRE, et al, editors, Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1992
Gardos G, Cole JO. The treatment of tardive dyskinesias. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 1503–11
Gerlach J, Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol plus biperiden, thiorida-zine, and clozapine. Psychopharmacology 1978; 59: 105–12
Alphs LD, Davis JM. Cholinergic treatments for tardive dyskinesia. In: Bannet J, Belmaker RH, editors. New directions in tardive dyskinesia research: modern problems in phar-macopsychiatry. Vol. 21. Basel: Karger, 1983; 168–86
Jeste DV, Wyatt RJ. Understanding and treating tardive dyskinesia. New York, Guildford Press, 1982
Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989; 99: 547–53
Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503–10
Fleischhaker WW, Hummer M, Kurz M, et al. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 1994; 55 Suppl. B: 78–81
Szymanski S, Maune R, Gordon MF, et al. A selective review of recent advances in the management of tardive dyskinesia. Psychiatr Ann 1993; 23: 209–15
Tarsy D, Kaufman D. Sethi KD, et al. An open-label study of botulinum toxin A for treatment of tardive dy stonia. Clin Neu-ropharmacol 1997; 20: 90–3
Burke RE. Neuroleptic-induced tardive dyskinesia variants. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. New York, Futura, 1992; 167–98
Chen C-H, Wei F-C, Koong F-J, et al. Association of Tag I polymorphism of dopamine. D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997; 41: 827–9
Steen VM, Lovlie R, MacEwan T, et al. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997; 2: 139–45